Fluoxetine, smoking, and history of major depression: A randomized controlled trial.
The study was a randomized placebo-controlled trial testing whether fluoxetine selectively enhances cessation for smokers with a history of depression. Euthymic smokers with (H+, n = 109) or without (H-, n = 138) a history of major depression received 60 mg fluoxetine or placebo plus group behavioral quit-smoking treatment for 12 weeks. Fluoxetine initially enhanced cessation for H+ smokers (p = .02) but subsequently impaired cessation regardless of depressive history. Six months after quit date, fluoxetine-treated participants were 3.3 times more likely to be smoking (p = .02). Further research is warranted to determine why high-dose fluoxetine produces continuing effects that oppose tobacco abstinence.
Spring
Bonnie
B
Psychology Department, University of Illinois at Chicago, Chicago, IL, USA. bspring@northwestern.edu
Doran
Neal
N
Pagoto
Sherry
S
McChargue
Dennis
D
Cook
Jessica Werth
JW
Bailey
Katherine
K
Crayton
John
J
Hedeker
Donald
D
D000293:Adolescent; D000328:Adult; D003865:Major Depressive Disorder / Q000188:drug therapy / Q000453:epidemiology / Q000523:psychology; D005473:Fluoxetine / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006801:Humans; D008875:Middle Aged; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use*; D012907:Smoking / Q000453:epidemiology*; D011795:Surveys and Questionnaires
D005473:Fluoxetine; D017367:Selective Serotonin Reuptake Inhibitors